The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia

Summary The protein C pathway serves as a modulating system with both anti-inflammatory and anticoagulant properties and is intimately involved in the pathophysiology of inflammation and sepsis. Treatment with recombinant human activated protein C (rhAPC) can reduce the mortality of severe sepsis. We investigated whether an elevation of plasma protein C levels to supranormal levels by infusion of a protein C zymogen concentrate has an effect on coagulation, protein C activation or inflammation in a human endotoxemia model. Eleven healthy male volunteers were enrolled in a double-blind, placebo-controlled two-way cross-over trial. Ten minutes after infusion of 2ng/kg endotoxin each volunteer received either placebo or a plasmaderived protein C zymogen concentrate (Ceprotin®, Baxter) (150 U/kg as a slow bolus infusion followed by 30 U/kg/h continuous infusion until 4 hours after LPS-infusion). Protein C antigen and activity increased 4– to 5-fold after infusion of the concentrate. APC was generated during endotoxin-induced inflammation in the placebo (1.6 fold increase) and the protein C period (4.0-fold increase).The increase of APC levels correlated with the TNF-α and IL-6 release in both periods (r=0.65–0.68; p<0.05) and paralleled the protein C antigen and activity levels in the period with supranormal protein C levels. Supra normal protein C levels resulted in slightly, although non-significant, lower tissue factor mRNA expression and thrombin generation (TAT, F1+2). Systemic inflammation (TNF-α, IL-6) was not influenced by protein C zymogen concentrate administration. Infusion of protein C zymogen was safe and no adverse effects occurred. The increase of protein C levels several fold above the normal range resulted in a proportional increase of the APC levels, but had no major anticoagulant, anti-inflammatory or profibrinolytic effects. Low grade endotoxemia itself induces significant protein C activation, which correlates with the TNF release.

[1]  O. Wagner,et al.  Effects of carbon monoxide inhalation during experimental endotoxemia in humans. , 2005, American journal of respiratory and critical care medicine.

[2]  C. Dempfle.  Coagulopathy of sepsis , 2004, Thrombosis and Haemostasis.

[3]  E. Abraham,et al.  New approaches to the treatment of sepsis. , 2003, Clinics in chest medicine.

[4]  B. Jilma,et al.  Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. , 2003, Blood.

[5]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[6]  P. Mulder,et al.  Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. , 2003, Critical care medicine.

[7]  M. Jourdain,et al.  Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study , 2003, Intensive Care Medicine.

[8]  H. Eichler,et al.  Pharmacodynamics of active site‐inhibited factor VIIa in endotoxin‐induced coagulation in humans , 2002, Clinical pharmacology and therapeutics.

[9]  J. Helterbrand,et al.  Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis , 2002, Clinical pharmacology and therapeutics.

[10]  H. Eichler,et al.  Acenocoumarol decreases tissue factor–dependent coagulation during systemic inflammation in humans , 2002, Clinical pharmacology and therapeutics.

[11]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[12]  C. Esmon,et al.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.

[13]  K. Reinhart,et al.  Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.

[14]  C. Esmon.  Role of Coagulation Inhibitors in Inflammation , 2001, Thrombosis and Haemostasis.

[15]  B. Lämmle,et al.  Protein C replacement in severe meningococcemia: rationale and clinical experience. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[17]  M. Rafferty,et al.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. , 2000, Blood.

[18]  V. Pettilä,et al.  Protein C substitution in sepsis-associated purpura fulminans , 2000, Critical care medicine.

[19]  José A Fernández,et al.  Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications , 2000, Critical care medicine.

[20]  E. Mayne,et al.  Meningococcal septicaemia: treatment with protein C concentrate , 2000, Intensive Care Medicine.

[21]  J. Hansen,et al.  Lepirudin blunts endotoxin-induced coagulation activation. , 2000, Blood.

[22]  J. Hansen,et al.  Heparin blunts endotoxin-induced coagulation activation. , 1999, Circulation.

[23]  H. Eichler,et al.  Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. , 1999, American journal of respiratory and critical care medicine.

[24]  T. van der Poll,et al.  Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. , 1997, Blood.

[25]  V. Rasi,et al.  Protein C in the treatment of coagulopathy in meningococcal disease , 1996, The Lancet.

[26]  C. Esmon,et al.  Protein C Inhibitor Is a Potent Inhibitor of the Thrombin-Thrombomodulin Complex (*) , 1995, The Journal of Biological Chemistry.

[27]  P. Turkington.  Cathepsin G, a regulator of human vitamin K, dependent clotting factors and inhibitors. , 1992, Thrombosis research.

[28]  J. Griffin,et al.  Direct detection of activated protein C in blood from human subjects. , 1992, Blood.

[29]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[30]  C. Esmon,et al.  Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.

[31]  K. Takatsuki,et al.  Effect of Protein C and Activated Protein C on Coagulation and Fibrinolysis in Normal Human Subjects , 1990, Thrombosis and Haemostasis.

[32]  P. Stolley,et al.  Sample size calculations for clinical pharmacology studies , 1986, Clinical pharmacology and therapeutics.

[33]  B. Jude,et al.  Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases , 2005, Intensive Care Medicine.

[34]  C. E. Ettingshausen,et al.  Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans , 1999, Seminars in thrombosis and hemostasis.

[35]  A. Giles,et al.  Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V. , 1997, Blood.

[36]  J. T. ten Cate,et al.  Coagulation Activation and Tissue Necrosis in Meningococcal Septic Shock: Severely Reduced Protein C Levels Predict a High Mortality , 1995, Thrombosis and Haemostasis.

[37]  M. Dreyfus,et al.  Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C Deficiency , 1995, Seminars in thrombosis and hemostasis.

[38]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. , 1990, Blood.